Background: CD-19 Chimeric Antigen Receptor – T (CAR-T) cell therapy is FDA approved for the treatment of primary refractory or recurrent Diffuse Large B-Cell Lymphoma (DLBCL) after two or more lines of systemic therapies have failed. The two commercially available products are Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel). In clinical trials, 54% of 111 patients […]